Overslaan en naar de inhoud gaan

 Wetenschapelijke artikelen

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Auteurs : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Jaar : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pagina's : 125

Chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.

Auteurs : Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A
Jaar : 2021
Journal : Lancet Oncol
Volume : 22
Pagina's : 858-871

How COVID-19 pandemic affected cancer progression: Three different scenarios evidenced by PET imaging.

Auteurs : Mileva M, Artigas C, Gebhart G, Flamen P, Karfis I
Jaar : 2020
Journal : Hell J Nucl Med
Volume : 23
Pagina's : 349-353